文献速递骨软组织肉瘤与黑色素瘤

III期黑色素瘤的辅助伊匹木单抗治疗:新格局与新问题

Adjuvant ipilimumab in stage III melanoma: New landscape, new questions.
PubMed 文献 · Eur J Cancer · 2016-11-04

欧洲癌症研究与治疗组织18071试验显示,高危III期黑色素瘤患者接受伊匹木单抗10 mg/kg辅助治疗较安慰剂死亡风险降低28%(HR 0.72,95.1%CI 0.58-0.88,P=0.001),无复发生存、无远处转移生存和总生存均获益相似,但3-4级免疫相关不良事件发生率达41.6%。

要点

  • 伊匹木单抗10 mg/kg辅助治疗使高危III期黑色素瘤死亡风险较安慰剂降低28%(HR 0.72,95.1%CI 0.58-0.88,P=0.001)。
  • 5年时伊匹木单抗组总生存、无远处转移生存和无复发生存分别较安慰剂组高11%、9%和11%。
  • 3-4级免疫相关不良事件在伊匹木单抗组为41.6%、安慰剂组为2.7%,仅42%患者接受超过4剂。

核心结论

  • 伊匹木单抗10 mg/kg辅助治疗可显著延长高危III期黑色素瘤患者的总生存,但伴随较高的免疫相关不良事件发生率。
  • 剂量与疗程、前哨淋巴结阳性患者是否需完整淋巴结清扫、干扰素剩余作用及新药可及性等问题仍待探讨。

研究设计与样本

  • 欧洲癌症研究与治疗组织18071试验,比较伊匹木单抗10 mg/kg与安慰剂辅助治疗高危III期黑色素瘤患者。

主要发现

  • 伊匹木单抗组较安慰剂组死亡风险降低28%(HR 0.72,95.1%CI 0.58-0.88,P=0.001)。
  • 5年时伊匹木单抗组总生存、无远处转移生存和无复发生存分别较安慰剂组高11%、9%和11%。
  • 两组全球健康生活质量评分无显著差异。
  • 仅42%患者接受超过4剂伊匹木单抗,仅28.9%患者治疗超过1年。
  • 3-4级免疫相关不良事件在伊匹木单抗组为41.6%,安慰剂组为2.7%。

临床怎么用

  • 作者认为靶向药物和抗程序性细胞死亡蛋白1(anti-PD-1)药物的 ongoing 试验可能在未来几年带来重要额外结果,将重新定义III期患者的治疗方式。
  • 作者指出新治疗的定价将决定可及性以及患者能否真正从新治疗选择中获益。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The recently reported significant prolongation of overall survival with ipilimumab as adjuvant in high-risk stage III melanoma patients represents an important event in the adjuvant treatment landscape. The European Organisation for Research and Treatment of Cancer 18071 trial demonstrated a 28% reduction in risk of death in patients treated with ipilimumab at 10 mg/kg (hazard ratio for death, 0.72; 95.1% CI, 0.58-0.88; P = 0.001) compared with placebo. All end-points-recurrence-free survival (RFS), distant-metastasis-free survival (DMFS) and overall survival (OS)-showed similar benefits. Survival rates at 5 years in ipilimumab-treated patients were OS 11%, DMFS 9% and RFS 11% higher than in placebo-treated patients. Global Health quality-of-life scores were not significantly different between treatment arms, in spite of significant adverse event rates that resulted in only 42% of patients receiving more than four doses of ipilimumab and only 28.9% of patients going beyond 1 year of treatment. Grades 3-4 immune-related adverse events occurred in 41.6% of ipilimumab-treated patients and in 2.7% of placebo-treated patients. One can speculate on dose and duration of treatment, as well as on the requirement for complete lymph-node dissection in sentinel-node-positive patients. The remaining role of interferons will be discussed regarding differences in sensitivity profiles-such as in ulcerated melanoma versus non-ulcerated melanoma-and access to new drugs. Ongoing trials with targeted agents and with anti programmed cell death protein 1 (anti-PD-1) agents may bring significant additional results in the next few years that will redefine how we treat stage III patients. Overall, pricing of new treatments will determine access and whether patients will actually benefit from new treatment options.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Eggermont AM. Adjuvant ipilimumab in stage III melanoma: New landscape, new questions. Eur J Cancer. 2016. PMID: 27816830. doi:10.1016/j.ejca.2016.10.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。